Doomed from the TERT? A Two-Stage Model of Tumorigenesis in IDH-Wild-Type Glioblastoma

被引：10

作者：

Stead, Lucy F. ^{[1
]}

Verhaak, Roel G. W. ^{[2
]}

机构：

[1] Univ Leeds, Leeds Inst Med Res St Jamess, Leeds LS9 7TF, W Yorkshire, England

[2] Jackson Lab Genom Med, Farmington, CT 06032 USA

来源：

CANCER CELL | 2019年 / 35卷 / 04期

关键词：

TUMOR EVOLUTION;

D O I：

10.1016/j.ccell.2019.03.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Using longitudinal molecular profiling, Korber et al. propose in this issue of Cancer Cell that IDH-wild-type glioblastomas initiate years pre-diagnosis with chromosome-level alterations that drive cell proliferation but require survival-promoting mutations, commonly in the TERT promoter, to form a detectable tumor. Multiple subclones drive disease progression, creating a therapeutic challenge.

引用

页码：542 / 544

页数：3

共 50 条

[31] Impact of Timing of Surgery and Adjuvant Treatment on Survival of Adult IDH-wild-type Glioblastoma: A Single-center Study of 392 Patients
Natukka, Tuomas
Haapasalo, Joonas
Kivioja, Tomi
Rajala, Linnea
Raitanen, Jani
Nevalainen, Jaakko
Lahtela, Sirpa-Liisa
Nordfors, Kristiina
Rauhala, Minna
Jukkola, Arja
Frosen, Juhana
Helen, Pauli
Auvinen, Anssi
Haapasalo, Hannu
WORLD NEUROSURGERY, 2023, 177 : E785 - E792
[32] TERT promoter mutation: is it enough to call a WHO grade II astrocytoma IDH wild-type glioblastoma?
Giannini, Caterina
Giangaspero, Felice
NEURO-ONCOLOGY, 2021, 23 (06) : 865 - 866
[33] TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma
Kikuchi, Zensho
Shibahara, Ichiyo
Yamaki, Tetsu
Yoshioka, Ema
Shofuda, Tomoko
Ohe, Rintaro
Matsuda, Ken-ichiro
Saito, Ryuta
Kanamori, Masayuki
Kanemura, Yonehiro
Kumabe, Toshihiro
Tominaga, Teiji
Sonoda, Yukihiko
NEURO-ONCOLOGY ADVANCES, 2020, 2 (01)
[34] Retraction Note: Tumour microenvironment programming by an RNA–RNA-binding protein complex creates a druggable vulnerability in IDH-wild-type glioblastoma
Lele Wu
Zheng Zhao
Yong Jae Shin
Yiyun Yin
Anandhkumar Raju
Thamil Selvan Vaiyapuri
Khaireen Idzham
Miseol Son
Yeri Lee
Jason K. Sa
Joelle Yi Heng Chua
Bilal Unal
You Zhai
Wenhua Fan
Lijie Huang
Huimin Hu
Jayantha Gunaratne
Do-Hyun Nam
Tao Jiang
Vinay Tergaonkar
Nature Cell Biology, 2025, 27 (3) : 546 - 546
[35] Circadian rhythm of tumor promotion in the two-stage model of mouse tumorigenesis
Wille, JJ
CANCER LETTERS, 2003, 190 (02) : 143 - 149
[36] TERT C228T: A NOVEL MOLECULAR INDEPENDENT PROGNOSTIC FACTOR IN PATIENTS WITH GLIOBLASTOMA IDH WILD TYPE
Gorria, T.
Crous, C.
Marino, C.
Hernandez, A.
Sanz, C.
Domenech, M.
Parra, G.
Esteve-Codina, A.
Carrato, C.
Melendez, B.
Aldecoa, I.
Jares, P.
Gonzalez, J.
Esteve, A.
Cerda, G.
Alameda, F.
Munoz-Marmol, A.
Lopez-Martos, R.
Valduvieco, I.
Gonzalez-Ortiz, S.
Pineda, E.
Balana, C.
NEURO-ONCOLOGY, 2023, 25 : 79 - 79
[37] Effect of Extent of Resection on Survival of Patients with Glioblastoma, IDH-Wild-Type, WHO Grade 4 (WHO 2021): Systematic Review and Meta-Analysis
Jusue-Torres, Ignacio
Lee, Jonathan
V. Germanwala, Anand
Burns, Terry C.
Parney, Ian F.
WORLD NEUROSURGERY, 2023, 171 : E524 - E532
[38] Distribution differences in prognostic copy number alteration profiles in IDH-wild-type glioblastoma cause survival discrepancies across cohorts (vol 7, 99, 2019)
ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2019, 7 (01):
[39] MRI-Based Radiomics Combined with Deep Learning for Distinguishing IDH-Mutant WHO Grade 4 Astrocytomas from IDH-Wild-Type Glioblastomas
Hosseini, Seyyed Ali
Hosseini, Elahe
Hajianfar, Ghasem
Shiri, Isaac
Servaes, Stijn
Rosa-Neto, Pedro
Godoy, Laiz
Nasrallah, MacLean P.
O'Rourke, Donald M.
Mohan, Suyash
Chawla, Sanjeev
CANCERS, 2023, 15 (03)
[40] Complement Components in Peripheral Blood from Adult Patients with IDH Wild-Type Glioblastoma
Jonsson, Karolina Fornvik
Liljedahl, Emma
Osther, Kurt
Bengzon, Johan
Skattum, Lillemor Melander
Redebrandt, Henrietta Nittby
WORLD NEUROSURGERY, 2023, 177 : E742 - E747

← 1 2 3 4 5 →